The FDA has approved anakinra (Kineret Amgen Inc, Thousand Oaks, Calif) as adjunctive therapy for reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in patients 18 years of age or older in whom one or more disease-modifying antirheumatic drugs (DMARDs) have failed. Anakinra is indicated for use alone or in combination with DMARDs other than anti–tumor necrosis factor (TNF) therapies.
Safety and effectiveness of were evaluated in three randomized, placebo-controlled trials of 1392 patients at least 18 years of age with active RA. A fourth study assessed the drug's safety in 1414 similar patients who were DMARD free or received concurrent medications, including some DMARDs.
Schwetz BA. Rheumatoid Arthritis Treatment. JAMA. 2002;287(1):33. doi:10.1001/jama.287.1.33-JFD10013-3-1
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.